Dudediligence.

C4 Therapeutics, Inc

CCCCNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$15.4MSep ’24$5.2MDec ’24$7.2MMar ’25$6.5MJun ’25$11.2MSep ’25$11.0MDec ’25$6.2MMar ’26$6.6MJun ’26
Net income, by quarter
−$24.7MSep ’24−$34.6MDec ’24−$26.3MMar ’25−$26.0MJun ’25−$32.2MSep ’25−$20.5MDec ’25−$25.1MMar ’26−$23.6MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$45.8M$31.1M$20.8M$35.6M$35.9M
Operating income−$82.1M−$129.5M−$139.0M−$119.6M−$115.2M
Net income−$83.9M−$128.2M−$132.5M−$105.3M−$105.0M
Operating cash flow−$87.0M−$105.9M−$106.8M−$65.2M−$98.7M
Free cash flow−$88.2M−$111.4M−$108.5M−$65.3M−$99.3M
Cash$76.1M$29.8M$126.6M$55.5M$74.6M
Debt$10.8M$11.5M$0.00none on filenone on file
Shares outstanding48.7M49.0M60.5M70.6M96.9M